12:29 PM · 29 July 2025

Novo Nordisk plunges 16% after cutting FY guidance 🚨

Novo Nordisk's (NOVOB.DK) shares dip about 16% due to the company lowering its full-year 2025 sales and operating profit outlook. Previously, investors had higher expectations for Novo Nordisk’s growth rates, but the updated guidance now forecasts sales growth in the 8–14% range for the year, which is below earlier projections (13-21%).

Today’s moves are largely due to weaker-than-expected Wegovy sales in the U.S. obesity market. The updated sales outlook specifically cites reduced growth expectations for Wegovy in the U.S., as well as slower-than-expected market expansion and stronger competition, particularly from Eli Lilly's rival drug Zepbound.

NOVOB shares are back at multi-year lows after cutting forecast. Source: xStation 

 

4 August 2026, 9:54 PM

AMD Did Everything Right… But Only Right

4 August 2026, 9:33 PM

SpaceX Shares Drop 6% After Earnings 🚩 Is Space No Longer Enough for Wall Street?

4 August 2026, 7:04 PM

Daily Summary: Nasdaq 100 Up 3.2% – Is the Bull Market Back? (04.08.2026)

4 August 2026, 3:57 PM

US Open: S&P 500 at ATH, Strait of Hormuz nearing reopening, Palantir up 23%

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits